The principal objecfive of the Biostatistics Core will be to provide project investigators a centralized resource for statistical expertise. Statisfical issues will be addressed at all levels of investigation: from the design o experiments to the conclusions drawn from them, and from the maintenance of data quality to the modeling fo human studies and trials. In support of this objective, the specific aims ofthe Biostatistics Core include: 1. To collaborate with project investigators in the formulation of hypotheses and hypothesis testing strategies, and in the design of experiments. Phase I trials, and population studies. 2. To conduct the statistical analyses of data generated by project invesfigators including: descriptive summary statistics, data modeling, hypothesis tesfing, and methods of discovery. 3. To ensure that the following statistical principles are adhered to in all studies: modeling nuisance or block effects, controlling Type I error to produce reliable conclusions, using adequate sample sizes to control Type II error and avoid inconsistent conclusions, using randomization of conditions to avoid systematic errors, and decreasing measurement error to enhance precision. 4. To provide design expertise and oversight for the Phase I Trials and support the design of possible future Phase II trials. 5. To collaborate with the bioinformatics core for all microarray analyses. 6. To investigate or develop new statistical methodologies to direcfiy address difficult data or design problems. 7. To provide design and data analyfic support from senior biostafisficians for the new investigators responsible for the pilot projects.

Public Health Relevance

The SPORE requires a variety of statistical support, from modeling population longitudinal data to hypothesis testing strategies for mulfiple measures in donor cell experiments. Expertise in experimental and trial design, statistical genetics, multiplicity problems, microarray analyses, and mixed modeling, and familiarity with CLL and AML were the requirements used for designing the pool of expertise found in this Biostafisfics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140158-04
Application #
8380668
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$133,305
Indirect Cost
$63,889
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Walker, C J; Eisfeld, A-K; Genutis, L K et al. (2017) No evidence for microsatellite instability in acute myeloid leukemia. Leukemia 31:1474-1476
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2017) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res 77:207-218
Park, I-K; Blum, W; Baker, S D et al. (2017) E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia 31:502-505
Papaioannou, Dimitrios; Shen, Changxian; Nicolet, Deedra et al. (2017) Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A 114:E4641-E4647
Eisfeld, A-K; Kohlschmidt, J; Schwind, S et al. (2017) Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 31:1278-1285
Papaioannou, Dimitrios; Nicolet, Deedra; Volinia, Stefano et al. (2017) Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica 102:1391-1400
Wiczer, Tracy E; Levine, Lauren B; Brumbaugh, Jessica et al. (2017) Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 1:1739-1748
Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A et al. (2017) Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv 1:1584-1588
Mani, R; Yan, R; Mo, X et al. (2017) Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol 15:1115-1118

Showing the most recent 10 out of 223 publications